-

SHAREHOLDER ALERT: Robbins LLP Informs Investors of Class Action on Behalf of ViacomCBS, Inc. (VIAC) Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired ViacomCBS, Inc. (NASDAQ: VIAC) securities between March 22, 2021 and March 29, 2021, for violations of the Securities Exchange Act of 1934.

If you own shares of ViacomCBS, Inc. and suffered a loss, click here.

ViacomCBS, Inc. (VIAC) Shareholders Harmed When Goldman Sachs Group and Morgan Stanley Sold Shares

According to the complaint, Goldman Sachs Group Inc. and Morgan Stanley sold ViacomCBS, Inc. shares while in possession of material non-public information. Specifically, Goldman Sachs and Morgan Stanley knew Archegos Capital Management would need to fully liquidate its position in ViacomCBS based on margin call pressures. Goldman Sachs Group and Morgan Stanley sold billions worth of ViacomCBS securities with this knowledge, sending ViacomCBS stock into a tailspin and avoiding billions in losses. When the market learned the truth, investors suffered damages.

If you purchased shares of ViacomCBS, Inc. (VIAC) between March 22, 2021 and March 29, 2021, you have until December 28, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against ViacomCBS, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Informs Stockholders it is Investigating Potential Securities Claims Involving Wealthfront Corporation

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Wealthfront Corporation (NASDAQ: WLTH) to determine whether certain Wealthfront officers and directors violated securities laws and breached fiduciary duties to shareholders.Why Are We Investigating Wealthfront?Wealthfront completed its initial public offering in December 2025, offering 34,615,384 shares of common stock at $14.00 per share, including shares sold by the Company and selling stockholders. The Compa...

Robbins LLP Informs Stockholders It Is Investigating Potential Securities Claims Involving Hyliion Holdings Corp.

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Hyliion Holdings Corp. (AMEX: HYLN) to determine whether certain Hyliion Holdings officers and directors violated securities laws and breached fiduciary duties to shareholders. Hyliion is a power generator company whose primary product is the KARNQ Power Module.Why Are We Investigating Hyliion Holdings?Hyliion stock dropped 16% on Tuesday, June 23, 2026, following the release of a short-seller report from Pelica...

Robbins LLP Urges CAPR Stockholders to Contact the Firm for Information About the Class Action Against Capricor Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").The lawsuit alleges that Capricor Therapeutics misled investors regarding the path to FDA approval for its lead product candidate Deramiocel, a cell therapy to address cardiac and skeletal muscle compli...
Back to Newsroom